Non-small Cell Lung Cancer
📧 Sign up to get email alerts when something new happens for Non-small Cell Lung Cancer.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2022-03-02Clinical Trial Update: Fruquintinib Combined With Sintilimab and Chemotherapy in the Treatment of Non-Small Cell Lung Cancer [Phase 2]
Phase 2 trial evaluating fruquintinib with sintilimab and chemotherapy in non-small cell lung cancer.
-
CLINICAL_TRIALS trial_result · 2022-03-02Clinical Trial Update: Phase II Study on Sintilimab Combined With Docetaxel for Chemotherapy Failure Advanced NSCLC: the SUCCESS Study [Phase 2]
Phase II study evaluating sintilimab plus docetaxel for chemotherapy-failure advanced non-small cell lung cancer has completed.
-
FDA approval · 2022-02-28FDA Approved: ALUNBRIG — Supplemental Application (Takeda Pharmaceuticals America, Inc.)
The FDA approved a supplemental application for ALUNBRIG (brigatinib) submitted by Takeda Pharmaceuticals America, Inc.
-
CLINICAL_TRIALS trial_result · 2022-02-25Clinical Trial Update: A Prospective Multi-center Phase III Randomized Controlled Trial [Phase 3]
A Phase III randomized controlled trial update is reported for non-small cell lung carcinoma, with status currently UNKNOWN.
-
CLINICAL_TRIALS trial_result · 2022-02-24Clinical Trial Update: Efficacy and Safety of Almonertinib Combined With or Without Chemotherapy as an Adjuvant Treatment for Stage II-IIIA Non-small Cell Lung Carcinoma Following Complete Tumour Resection [Phase 3]
Phase 3 trial evaluating almonertinib with or without chemotherapy as adjuvant treatment after complete tumor resection in stage II-IIIA non…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2022-02-24Clinical Trial Update: Neoadjuvant Durvalumab Alone or in Combination With Novel Agents in Resectable Non-Small Cell Lung Cancer [Phase 2]
Phase 2 clinical trial evaluating neoadjuvant durvalumab alone or with novel agents in resectable early-stage non-small cell lung cancer has…
-
CLINICAL_TRIALS trial_result · 2022-02-23Clinical Trial Update: An Exploratory Study of Herombopag for Thrombocytopenia Induced by Chemotherapy Combined With Immunotherapy in NSCLC [Phase 2]
Phase 2 exploratory study investigating herombopag for chemotherapy-induced thrombocytopenia in non-small cell lung cancer treated with immu…
-
CLINICAL_TRIALS trial_result · 2022-02-17Clinical Trial Update: Predictive Biomarker for Efficacy and Safety of Combination of Chemotherapy and Tislelizumab in NSCLC [Phase 2]
A Phase 2 trial update investigating a predictive biomarker for the efficacy and safety of combining chemotherapy with tislelizumab in NSCLC…
-
CLINICAL_TRIALS trial_result · 2022-02-11Clinical Trial Update: Evaluating Crizotinib in the Neoadjuvant Setting in Patients With Non-small Cell Lung Cancer [Phase 2]
Phase 2 trial evaluating crizotinib as neoadjuvant therapy in patients with non-small cell lung cancer has completed with results posted.
-
CLINICAL_TRIALS trial_result · 2022-02-11Clinical Trial Update: Study of Ponatinib in Patients With Lung Cancer Preselected Using Different Candidate Predictive Biomarkers [Phase 2]
Phase 2 trial evaluating ponatinib in lung cancer patients preselected by predictive biomarkers; study completed with results posted.
-
CLINICAL_TRIALS trial_result · 2022-02-09Clinical Trial Update: Durvalumab and Tremelimumab ± Platinum-Based Chemotherapy in Patients With Metastatic Squamous or Non-Squamous NSCLC [Phase 2]
Phase 2 study evaluating durvalumab with tremelimumab, with or without platinum-based chemotherapy, in patients with metastatic non-small ce…
-
CLINICAL_TRIALS trial_result · 2022-02-09Clinical Trial Update: Study to Evaluate Safety, Efficacy, Pharmacokinetics And Pharmacodynamics Of Avelumab In Combination With Either Crizotinib Or PF-06463922 In Patients With NSCLC. (Javelin Lung 101) [Phase 1, Phase 2]
Early-phase trial evaluating safety, efficacy, pharmacokinetics, and pharmacodynamics of avelumab in combination with crizotinib or PF-06463…
-
CLINICAL_TRIALS trial_result · 2022-02-08Clinical Trial Update: Icotinib as an Adjuvant Therapy for Patients With Stage IIA-IIIA Adenocarcinoma With EGFR Mutation [Phase 2]
Phase 2 trial evaluating icotinib as adjuvant therapy for stage IIA-IIIA EGFR-mutant adenocarcinoma of the lung (non-small cell lung cancer)…
-
CLINICAL_TRIALS trial_result · 2022-02-08Clinical Trial Update: Apatinib Combined With Radiotherapy in Patient With BM From Drive Gene Negative NSCLC [Phase 2]
Phase 2 trial assessing apatinib combined with radiotherapy in brain metastases from driver-gene negative non-small cell lung cancer.
-
CLINICAL_TRIALS trial_result · 2022-02-03Clinical Trial Update: Combination Chemotherapy, Surgery, and Radiation Therapy in Treating Patients With Non-Small Cell Lung Cancer [Phase 2]
Phase 2 clinical trial evaluating combination chemotherapy, surgery, and radiation therapy for non-small cell lung cancer has completed with…
-
CLINICAL_TRIALS trial_result · 2022-01-26Clinical Trial Update: Alflutinib Versus Alflutinib Plus Chemotherapy for NSCLC [Phase 2, Phase 3]
Clinical trial comparing alflutinib alone versus alflutinib with chemotherapy in non-small cell lung cancer (NSCLC) across Phase 2 and Phase…
-
CLINICAL_TRIALS trial_result · 2022-01-26Clinical Trial Update: Tislelizumab Plus Chemotherapy as First-Line Treatment for Advanced Squamous NSCLC With Brain Metastases [Phase 2]
Phase 2 trial investigating tislelizumab plus chemotherapy as first-line treatment for advanced squamous non-small cell lung cancer with bra…
-
CLINICAL_TRIALS trial_result · 2022-01-26Clinical Trial Update: Clinical Trial of GAIA-102 for Advanced and Relapse NSCLC [Phase 1, Phase 2]
A clinical trial update for GAIA-102 in advanced and relapse non-small cell lung cancer across Phase 1 and Phase 2 stages; current status is…
-
CLINICAL_TRIALS trial_result · 2022-01-24Clinical Trial Update: A Study to Evaluate and Compare the Efficacy and Safety of XZP-3621 Versus Crizotinib [Phase 3]
Phase 3 trial comparing XZP-3621 to crizotinib in non-small cell lung cancer is ongoing with unknown status.
-
FDA approval · 2022-01-21FDA Approved: TABRECTA — Supplemental Application (Novartis Pharmaceuticals Corporation)
FDA approved a supplemental application for TABRECTA (capmatinib) submitted by Novartis Pharmaceuticals Corporation.
-
CLINICAL_TRIALS trial_result · 2022-01-21Clinical Trial Update: A Phase II Clinical Trial to Evaluate HLX208 in Advanced Non-small Cell Lung Cancer Patients With BRAF V600 Mutation [Phase 2]
Phase II clinical trial evaluating HLX208 in advanced non-small cell lung cancer with BRAF V600 mutation.
-
FDA approval · 2022-01-19FDA Approved: TAGRISSO — Supplemental Application (AstraZeneca Pharmaceuticals LP)
The FDA approved a supplemental application for Tagrisso (osimertinib) by AstraZeneca, resulting in updated labeling for the drug.
-
CLINICAL_TRIALS trial_result · 2022-01-18Clinical Trial Update: Adjuvant Targeted-therapy for Patients With Resected High-risk EGFR-mutant Stage IB-IIA Non-small Cell Lung Carcinoma [Phase 2]
Phase 2 clinical trial update evaluating adjuvant targeted therapy for patients with resected high-risk EGFR-mutant stage IB-IIA non-small c…
-
CLINICAL_TRIALS trial_result · 2022-01-14Clinical Trial Update: Tislelizumab as Cross-line Treatment for Advanced NSCLC [Phase 2]
Phase 2 clinical trial evaluating tislelizumab as a cross-line treatment for advanced non-small-cell lung cancer.
-
CLINICAL_TRIALS trial_result · 2022-01-12Clinical Trial Update: BATTLE-2 Program: A Biomarker-Integrated Targeted Therapy Study in Previously Treated Patients With Advanced Non-Small Cell Lung Cancer [Phase 2]
Phase 2 trial update for the BATTLE-2 program in previously treated advanced non-small cell lung cancer evaluating a biomarker-integrated ta…